nach oben

Die Onkologie

Erschienen in:

01.05.2014 | Leitthema

Spätschäden und Survivorship nach Behandlung des Hodgkin-Lymphoms

verfasst von: Dr. K. Behringer, T.V. Halbsguth, P. Borchmann

Erschienen in: Die Onkologie | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Im Hinblick auf die eindrucksvollen Remissionsraten, die in den letzten Jahren in der Therapie des Hodgkin-Lymphoms (HL) erzielt wurden, gewinnen die therapieinduzierten Spätkomplikationen einen immer größeren Stellenwert.

Ergebnisse

Zu der wichtigsten therapieinduzierten Komplikation zählt die Entwicklung von Zweitneoplasien, die ein wesentliches Mortalitätsrisiko für Langzeitüberlebende eines HL darstellt. Die Organtoxizitäten umfassen kardiale, pulmonale und gonadale Schäden. Letztere sind besonders für junge Survivor mit noch nicht abgeschlossener Familienplanung relevant. Vor Einleitung der Therapie soll über die Möglichkeit fertilitätserhaltender Maßnahmen aufgeklärt werden. Auch die allgemeine Lebensqualität von HL-Patienten ist langfristig niedriger als die von nichterkrankten gleichaltrigen Menschen. Führendes Problem hierbei ist die Entwicklung von Fatigue, die häufig ein langfristiges Problem darstellt.

Diskussion

Die Therapiestrategien aktueller klinischer Studien zielen auf eine Reduktion von therapiebedingen Spätschäden bei gleichzeitiger Beibehaltung der guten Tumorkontrolle.

Aleman BM et al (2003) Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 21:3431–3439PubMedCrossRef

Hodgson DC et al (2007) Long-term solid cancer risk among 5-year survivors of Hodgkin’s lymphoma. J Clin Oncol 25:1489–1497PubMedCrossRef

Behringer K et al (2004) Solid tumors in patients treated for Hodgkin’s disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 15:1079–1085PubMedCrossRef

Leeuwen FE van et al (1994) Second cancer risk following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol 12:312–325PubMed

Dores GM et al (2002) Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol 20:3484–3494PubMedCrossRef

Ng AK et al (2002) Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 100:1989–1996PubMedCrossRef

Ng AK et al (2002) Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol 20:2101–2108PubMedCrossRef

Hancock S, Tucker M, Hoppe R (1993) Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 85:25–31PubMedCrossRef

Leeuwen FE van et al (2003) Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst 95:971–980PubMedCrossRef

10.

Wolden SL et al (2000) Management of breast cancer after Hodgkin’s disease. J Clin Oncol 18:765–772PubMed

11.

Franklin J et al (2006) Second malignancy risk associated with treatment of Hodgkin’s lymphoma: meta-analysis of the randomised trials. Ann Oncol 17:1749–1760PubMedCrossRef

12.

Gervais-Fagnou DD et al (1999) Breast cancer in women following supradiaphragmatic irradiation for Hodgkin’s disease. Oncology 57:224–231PubMedCrossRef

13.

Van Leeuwen FE, Klokmann WJ, Hagenbeek A (1994) Second cancer risk following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol 12:312

14.

De Bruin ML et al (2009) Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 27:4239–4246CrossRef

15.

Rancea M et al (2013) Hodgkin’s lymphoma in adults: diagnosis, treatment and follow-up. Dtsch Arztebl Int 110:177–183, 183e1–3PubMedCentralPubMed

16.

Swerdlow AJ et al (2000) Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 18:498–509PubMed

17.

Foss Abrahamsen A et al (2002) Long-term risk of second malignancy after treatment of Hodgkin’s disease: the influence of treatment, age and follow-up time. Ann Oncol 13:1786–1791CrossRef

18.

Schoenfeld JD et al (2012) Lung malignancies after Hodgkin lymphoma: disease characteristics, detection methods and clinical outcome. Ann Oncol 23:1813–1818PubMedCrossRef

19.

Milano MT et al (2011) Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patients. Cancer 117:5538–5547PubMedCrossRef

20.

Aberle DR et al (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395–409PubMedCrossRef

21.

Aberle DR et al (2013) Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med 369:920–931PubMedCrossRef

22.

Mauch P et al (1996) Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin’s disease: long-term analysis of risk factors and outcome. Blood 87:3625–3632PubMed

23.

Josting A et al (2003) Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3440–3446PubMedCrossRef

24.

Schonfeld SJ et al (2006) Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients. J Natl Cancer Inst 98:215–218PubMedCrossRef

25.

Engert A et al (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548–4554PubMedCrossRef

26.

Henry-Amar M, Joly F (1996) Late complications after Hodgkin’s disease. Ann Oncol 7(Suppl 4):115–126PubMedCrossRef

27.

Tucker M, Coleman C, Cox R (1988) Risk of second cancers after treatment for Hodgkin’s disease. N Engl J Med 318:76–81PubMedCrossRef

28.

Rueffer U et al (2001) Non-Hodgkin’s lymphoma after primary Hodgkin’s disease in the German Hodgkin’s Lymphoma Study Group: incidence, treatment, and prognosis. J Clin Oncol 19:2026–2032PubMed

29.

Aleman BM et al (2007) Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109:1878–1886PubMedCrossRef

30.

Swerdlow AJ et al (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 99:206–214PubMedCrossRef

31.

Aviles A et al (2005) Late cardiac toxicity secondary to treatment in Hodgkin’s disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma 46:1023–1028PubMedCrossRef

32.

Dalen EC van et al (2008) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2:CD003917PubMed

33.

Dalen EC van et al (2006) Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 4:CD005008PubMed

34.

Rueffer U et al (2001) Male gonadal dysfunction in patients with Hodgkin’s disease prior to treatment. Ann Oncol 12:1307–1311PubMedCrossRef

35.

Sieniawski M et al (2008) Assessment of male fertility in patients with Hodgkin’s lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol 19:1795–1801PubMedCrossRef

36.

Viviani S et al (1991) Testicular dysfunction in Hodgkin’s disease before and after treatment. Eur J Cancer 27:1389–1392PubMedCrossRef

37.

Gandini L et al (2003) Testicular cancer and Hodgkin’s disease: evaluation of semen quality. Hum Reprod 18:796–801PubMedCrossRef

38.

Holoch P, Wald M (2011) Current options for preservation of fertility in the male. Fertil Steril 96:286–290PubMedCrossRef

39.

Hsiao W et al (2011) Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction: the Weill Cornell experience. J Clin Oncol 29:1607–1611PubMedCrossRef

40.

Casteren NJ van et al (2009) Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer 52:108–112PubMedCrossRef

41.

Beek RD van et al (2007) Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin’s lymphoma with chemotherapy during childhood. Hum Reprod 22:3215–3222PubMedCrossRef

42.

Kiserud CE et al (2009) Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer 100:455–463PubMedCentralPubMedCrossRef

43.

Bonadonna G et al (1984) Gonadal damage in Hodgkin’s disease from cancer chemotherapeutic regimens. Arch Toxicol Suppl 7:140–145PubMedCrossRef

44.

Kulkarni S et al (1997) Gonadal function following ABVD therapy for Hodgkin’s disease. Am J Clin Oncol 20:354–357PubMedCrossRef

45.

Behringer K et al (2013) Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 31:231–239PubMedCrossRef

46.

Wolff M von et al (2009) Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy – a technique in its infancy but already successful in fertility preservation. Eur J Cancer 45:1547–1553CrossRef

47.

Demeestere I et al (2007) Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin’s disease. Oncologist 12:1437–1442PubMedCrossRef

48.

Donnez J, Dolmans MM (2011) Preservation of fertility in females with haematological malignancy. Br J Haematol 154:175–184PubMedCrossRef

49.

Wo JY, Viswanathan AN (2009) Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys 73:1304–1312PubMedCentralPubMedCrossRef

50.

Wallace WH, Thomson AB, Kelsey TW (2003) The radiosensitivity of the human oocyte. Hum Reprod 18:117–121PubMedCrossRef

51.

Andre M et al (1997) Results of three courses of adriamycin, bleomycin, vindesine, and dacarbazine with subtotal nodal irradiation in 189 patients with nodal Hodgkin’s disease (stage I, II and IIIA). Hematol Cell Ther 39:59–65PubMedCrossRef

52.

Bonadonna G (1994) Modern treatment of malignant lymphomas: a multidisciplinary approach? The Kaplan Memorial Lecture. Ann Oncol 5(Suppl 2):5–16PubMedCrossRef

53.

Brusamolino E et al (2000) Treatment of early-stage Hodgkin’s disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity. Haematologica 85:1032–1039PubMed

54.

Hodgson DC et al (2007) Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 25:11–15PubMedCrossRef

55.

Waxman JH et al (1987) Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol 19:159–162PubMedCrossRef

56.

Behringer K et al (2010) No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol 21:2052–2060PubMedCrossRef

57.

Giuseppe L et al (2007) Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 12:141–147PubMedCrossRef

58.

Badawy A et al (2009) Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91:694–697PubMedCrossRef

59.

Sverrisdottir A et al (2009) Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 117:561–567PubMedCrossRef

60.

Del Mastro L et al (2011) Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 306:269–276

61.

Blumenfeld Z et al (2008) Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril 89:166–173PubMedCrossRef

62.

Castelo-Branco C et al (2007) Use of gonadotropin-releasing hormone agonists in patients with Hodgkin’s disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil Steril 87:702–705PubMedCrossRef

63.

Nitzschke M et al (2010) GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin’s lymphoma patients. Arch Gynecol Obstet 282:83–88PubMedCrossRef

64.

Huser M et al (2008) Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Hum Reprod 23:863–868PubMedCrossRef

65.

Behringer K et al (2012) Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol 23:1818–1825PubMedCrossRef

66.

Loge J et al (1999) Hodgkin’s disease survivors more fatigued than the general population. J Clin Oncol 17:253–261PubMed

67.

Fobair P et al (1986) Psychosocial problems among survivors of Hodgkin’s disease. J Clin Oncol 4:805–814PubMed

68.

Roper K et al (2009) Health-related quality of life in adults with Hodgkin’s disease: the state of the science. Cancer Nurs 32(6):E1–E17 (quiz E18–E19)PubMedCrossRef

69.

Ruffer JU et al (2003) Fatigue in long-term survivors of Hodgkin’s lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 39:2179–2186PubMedCrossRef

70.

Ganz PA et al (2003) Health status and quality of life in patients with early-stage Hodgkin’s disease treated on Southwest Oncology Group Study 9133. J Clin Oncol 21:3512–3519PubMedCrossRef

71.

Heutte N et al (2009) Quality of life after successful treatment of early-stage Hodgkin’s lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol 10:1160–1170PubMedCrossRef

72.

McNeely ML, Courneya KS (2010) Exercise programs for cancer-related fatigue: evidence and clinical guidelines. J Natl Compr Canc Netw 8:945–953PubMed

73.

Schellong G, Riepenhausen M, Ehlert K et al (2014) Brustkrebs bei jungen Frauen nach Therapie eines Hodgkin-Lymphoms im Kindes- und Jugendalter: Eine Beobachtungsstudie mit bis zu 33 Jahren Follow-up. Dtsch Arztebl Int 111:3–9PubMedCentralPubMed

74.

Eichenauer DA, Haverkamp H, Behringer K et al (2010) Secondary MDS/AML in hodgkin lymphoma patients treated within German Hodgkin Study Group (GHSG) clinical trials after introduction of the BEACOPP protocol. Blood 116:2682 (ASH Annual Meeting Abstracts)

Titel: Spätschäden und Survivorship nach Behandlung des Hodgkin-Lymphoms
verfasst von: Dr. K. Behringer
T.V. Halbsguth
P. Borchmann
Publikationsdatum: 01.05.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Die Onkologie / Ausgabe 5/2014
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI: https://doi.org/10.1007/s00761-013-2638-2

Neu im Fachgebiet Onkologie

10.04.2024 | PSA-Screening | Nachrichten

Springer Medizin

Spätschäden und Survivorship nach Behandlung des Hodgkin-Lymphoms

Zusammenfassung

Hintergrund

Ergebnisse

Diskussion

Neu im Fachgebiet Onkologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Senkt Schlafapnoe das Überleben bei Lungenkrebs?

Update Onkologie

Springer Medizin

Zusammenfassung

Hintergrund

Ergebnisse

Diskussion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2014

Aktueller Stellenwert der Positronenemissionstomographie beim Hodgkin-Lymphom

Zirkulierende micro-RNA als Responsemarker beim Ösophaguskarzinom

Rolle der Strahlentherapie beim Hodgkin-Lymphom

Erweiterter RAS-Mutationsstatus

Paraneoplastische Gerinnungsstörungen

Zelladhäsionsmolekül L1CAM

Neu im Fachgebiet Onkologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Senkt Schlafapnoe das Überleben bei Lungenkrebs?

Update Onkologie